semaglutide vs sglt2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 Inhibitors vs. GLP-1 Agonists

This information helps clinicians provide better-informed advice and make appropriate adjustments to your treatment plan if needed

www.rddiagnostics.com CONTENTS 1) Intended Use 2) Clinical Background (Summary and Explanation of the Test) 3) Principle of the Assay 4) Kit Contents 5) Reagents / Materials required but not provided 6) Precautions - Safety and Operating 7) Sample Collection 8) Reagent Reconstitution 9) Assay Procedures 10) Calculation of Results 11) Quality Assurance 12) Expected Values 13) Comparative Protocol Evaluation 14) Performance Characteristics 15) Limitations of Use 16) Summary of Protocols 17) References 1

A better understanding of GLP-1R pleiotropic signalling and the underlying physiological consequences might provide new avenues for the development of drugs with novel modes of action that have the potential to provide greater therapeutic value while possibly avoiding unwanted side effects 12,13

Factors like stress, menopause, insulin resistance, and thyroid issues can trigger hormonal weight gain